OncoMatch/Clinical Trials/NCT06365671
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Is NCT06365671 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Relmacabtagene autoleucel (relma-cel) for b-cell non hodgkin lymphoma.
Treatment: Relmacabtagene autoleucel (relma-cel) — Clinical trial for the safety and efficacy of CD19 CAR-T following autologous hematopoietic stem cell transplantation (ASCT) for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) with High-Risk Prognostic Factors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: TP53 alterations
Presence of at least one of the following high-risk prognostic factors: (1) extranodal involvement; (2) maximum diameter of the bulky mass ≥5 cm; (3) TP53 gene alterations
Allowed: MYC rearrangement
high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement
Allowed: BCL2 rearrangement
high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement
Allowed: BCL6 rearrangement
high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody
individuals must have received anti-CD20 monoclonal antibody and anthracycline-containing chemotherapy regimen
Must have received: anthracycline
individuals must have received anti-CD20 monoclonal antibody and anthracycline-containing chemotherapy regimen
Cannot have received: autologous stem cell transplant
History of autologous or allogeneic stem cell transplantation
Cannot have received: allogeneic stem cell transplant
History of autologous or allogeneic stem cell transplantation
Cannot have received: CAR-T cell therapy targeting CD19
Prior chimeric antigen receptor cellular immunotherapy targeting CD19
Lab requirements
Kidney function
Serum creatinine ≤1.5 ULN, or creatinine clearance ≥ 30 mL/min
Liver function
ALT/AST ≤ 3 ULN; total bilirubin ≤1.5 mg/dL (<3x ULN in patients with Gilbert's syndrome, cholestasis due to hepatoportal compression adenopathy, biliary obstruction in patients with liver involvement or lymphoma)
Cardiac function
Cardiac ejection fraction ≥ 40%
Adequate renal and hepatic function defined as: Serum alanine aminotransferase (ALT/AST) ≤ 3 upper limit of normal (ULN); Total bilirubin ≤1.5 mg/dL(<3 times ULN in patients with Gilbert's syndrome, cholestasis due to hepatoportal compression adenopathy, biliary obstruction in patients with liver involvement or lymphoma); Serum creatinine ≤1.5 ULN, or creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min; Cardiac ejection fraction ≥ 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06365671 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, allogeneic stem cell transplant, CAR-T cell therapy targeting CD19 disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages